Plain-English translation of NCT05748834 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications— and —to see if they work well together to treat advanced HER2-positive breast cancer. HER2-positive means cancer cells have extra copies of a specific growth protein, which these medications are designed to target. The study will enroll 36 people and will first carefully monitor the first 6 participants to make sure the combination is safe before expanding.
People with advanced HER2-positive breast cancer often need new treatment options after their cancer stops responding to earlier therapies. This medication combination may offer another chance to fight the disease when other treatments have stopped working.
You likely qualify if…
You likely don't qualify if…
You would take as a pill by mouth twice daily throughout the study, and receive as an IV infusion on day 1 of each 28-day cycle. The first 6 participants will have weekly check-ins during their first cycle so doctors can carefully watch for side effects. If everything goes well, the study will continue enrolling more participants. You'll have regular visits for blood tests, scans, and check-ins to see how the treatment is working and how you're feeling.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States